- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Dark urine.
Displaying page 1 of 1.
EudraCT Number: 2019-004981-16 | Sponsor Protocol Number: 1991-201-008 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Editas Medicine, Inc. | |||||||||||||
Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen... | |||||||||||||
Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001516-30 | Sponsor Protocol Number: GDX-44-007 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:GUERBET | ||||||||||||||||||
Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI. | ||||||||||||||||||
Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Ongoing) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001374-34 | Sponsor Protocol Number: 6630-0450-01 | Start Date*: 2014-06-11 |
Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG | ||
Full Title: A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing pro... | ||
Medical condition: healthy volunteers; intended indication is the treatment of acute wounds such as abrasions, cuts, scratches, laceration, blistering burns and sunburns | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004000-33 | Sponsor Protocol Number: INZ701-201 | Start Date*: 2021-06-10 | |||||||||||
Sponsor Name:Inozyme Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i... | |||||||||||||
Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
